AIDS and Behavior

, Volume 17, Issue 1, pp 94–103 | Cite as

Adherence to Hepatitis C Virus Therapy in HIV/Hepatitis C-Coinfected Patients

  • Vincent Lo ReIIIEmail author
  • Valerie Teal
  • A. Russell Localio
  • Valerianna K. Amorosa
  • David E. Kaplan
  • Robert Gross
Original Paper


Adherence to hepatitis C virus (HCV) therapy has been incompletely examined among HIV-infected patients. We assessed changes in interferon and ribavirin adherence and evaluated the relationship between adherence and early (EVR) and sustained virologic response (SVR). We performed a cohort study among 333 HIV/HCV-coinfected patients who received pegylated interferon and ribavirin between 2001 and 2006 and had HCV RNA before and after treatment. Adherence was calculated over 12-week intervals using pharmacy refills. Mean interferon and ribavirin adherence declined 2.5 and 4.1 percentage points per 12-week interval, respectively. Among genotype 1/4 patients, EVR increased with higher ribavirin adherence, but this association was less strong for interferon. SVR among these patients was higher with increasing interferon and ribavirin adherence over the first, second, and third, but not fourth, 12-week intervals. Among HIV/HCV patients, EVR and SVR increased with higher interferon and ribavirin adherence. Adherence to both antivirals declined over time, but more so for ribavirin.


Adherence Hepatitis C virus HIV Antiviral therapy Pegylated interferon Ribavirin 



Early virologic response


Hepatitis C virus


Sustained virologic response


Veterans affairs


La adhesión a la hepatitis C (HCV), la terapia ha sido completamente examinado entre pacientes infectados por HIV. Se evaluaron los cambios en el interferón y la ribavirina y la adhesión se evaluó la relación entre la adherencia y la respuesta virológica temprana (EVR) y sostenida (SVR). Se realizó un estudio de cohortes entre los 333 con HIV/HCV-coinfectados pacientes que recibieron interferón pegilado y ribavirina entre 2001 y 2006 y tuvo el HCV RNA antes y después del tratamiento. El cumplimiento se calcula en intervalos de 12 semanas utilizando recambios de farmacia. La media de interferón y la adherencia de ribavirina disminuyó 2,5 y 4,1 puntos porcentuales por intervalo de 12 semanas, respectivamente. Entre los genotipos 1/4 de los pacientes, EVR aumenta con la mayor adherencia de ribavirina, pero esta asociación era menos fuerte que el interferón. SVR en estos pacientes fue mayor con el aumento de adhesiones interferón y ribavirina durante el primer segundo, y tercero, pero no el cuarto, 12 semanas de intervalo. Entre el HIV/HCV los pacientes, EVR y SVR aumenta con la más alta de interferón y ribavirina la adhesión. El cumplimiento de ambos antivirales disminuido con el tiempo, pero más aún de la ribavirina.



This work was supported by the National Institutes of Health [K01-AI070001 to V. L. R.] and a Department of Veterans Affairs Competitive Pilot Project Fund grant [to V. K. A.]. This material is based upon work supported in part by the Department of Veterans Affairs. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.

Conflict of interest



  1. 1.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS. 2007;21:1073–89.PubMedCrossRefGoogle Scholar
  3. 3.
    Yee HS, Currie SL, Darling JM, Wright TL. Management and treatment of hepatitis C viral infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center program and the National Hepatitis C program office. Am J Gastroenterol. 2006;101:2360–78.PubMedCrossRefGoogle Scholar
  4. 4.
    Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–48.PubMedCrossRefGoogle Scholar
  5. 5.
    Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50:407–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15:2109–17.PubMedCrossRefGoogle Scholar
  9. 9.
    Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146:564–73.PubMedGoogle Scholar
  10. 10.
    Lo Re V 3rd, Amorosa VK, Localio AR, et al. Adherence to hepatitis C virus therapy and early virologic outcomes. Clin Infect Dis. 2009;48:186–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients’ self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;28:289–93.PubMedCrossRefGoogle Scholar
  12. 12.
    Howard AA, Arnsten JH, Lo Y, et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175–82.PubMedCrossRefGoogle Scholar
  13. 13.
    Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women. Clin Infect Dis. 2007;45:1377–85.PubMedCrossRefGoogle Scholar
  14. 14.
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Avants SK, Margolin A, Warburton LA, et al. Predictors of nonadherence to HIV-related medication regimens during methadone stabilization. Am J Addict. 2001;10:69–78.PubMedCrossRefGoogle Scholar
  16. 16.
    Soyka M, Lieb M, Kagerer S, et al. Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trial. J Clin Psychopharmacol. 2008;28:699–703.PubMedCrossRefGoogle Scholar
  17. 17.
    Backus LI, Gavrilov S, Loomis TP, et al. Clinical Case Registries: simultaneous local and national disease registries for population quality management. J Am Med Inform Assoc. 2009;16:775–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321–33.PubMedCrossRefGoogle Scholar
  19. 19.
    Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57:1107–10.PubMedCrossRefGoogle Scholar
  21. 21.
    Lo Re V 3rd, Teal V, Localio AR, et al. Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study. Ann Intern Med. 2011;155:353–60.PubMedGoogle Scholar
  22. 22.
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: Wiley; 2004.Google Scholar
  24. 24.
    Berlin JA, Kimmel SE, Ten Have TR, Sammel MD. An empirical comparison of several clustered data approaches under confounding due to cluster effects in the analysis of complications of coronary angioplasty. Biometrics. 1999;55:470–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia: Lippincott Williams and Wilkins; 1998.Google Scholar
  26. 26.
    McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Raptopoulou M, Tsantoulas D, Vafiadi I, et al. The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. J Viral Hepat. 2005;12:91–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007;5:124–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007;132:103–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Opravil M, Torriani F, Sasadeusz J, et al. Treatment exposure and sustained virologic response (SVR) in genotype 1 patients treated with peginterferon alfa-2a (40KD) + ribavirin in APRICOT (AIDS PEGASYS Ribavirin International Co-Infection Trial). In 45th interscience conference on antimicrobial agents and chemotherapy, Washington, DC. 16–19 Dec 2005 (Abstract V-1179).Google Scholar
  31. 31.
    Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr. 2009;50:529–36.PubMedCrossRefGoogle Scholar
  32. 32.
    Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165:1147–52.PubMedCrossRefGoogle Scholar
  33. 33.
    Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455–61.PubMedCrossRefGoogle Scholar
  34. 34.
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.PubMedCrossRefGoogle Scholar
  35. 35.
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.PubMedCrossRefGoogle Scholar
  36. 36.
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–28.PubMedCrossRefGoogle Scholar
  37. 37.
    Elixhauser A, Eisen SA, Romeis JC, Homan SM. The effects of monitoring and feedback on compliance. Med Care. 1990;28:882–93.PubMedCrossRefGoogle Scholar
  38. 38.
    Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care. 1988;26:814–23.PubMedCrossRefGoogle Scholar
  39. 39.
    Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21:1579–89.PubMedCrossRefGoogle Scholar
  40. 40.
    Heisler M, Hogan MM, Hofer TP, et al. When more is not better: treatment intensification among hypertensive patients with poor medication adherence. Circulation. 2008;117:2884–92.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Vincent Lo ReIII
    • 1
    • 2
    • 3
    Email author
  • Valerie Teal
    • 2
  • A. Russell Localio
    • 2
  • Valerianna K. Amorosa
    • 1
    • 3
  • David E. Kaplan
    • 3
    • 4
  • Robert Gross
    • 1
    • 2
    • 3
  1. 1.Division of Infectious Diseases, Department of MedicinePerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  2. 2.Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and BiostatisticsPerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  3. 3.Medicine Service, Philadelphia Veterans Affairs Medical CenterPhiladelphiaUSA
  4. 4.Division of Gastroenterology, Department of MedicinePerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations